HORSHAM, PA — Kyfora Bio has introduced KyFect™ – AAV, a specialized transfection reagent engineered to improve scalability and yield in the production of adeno-associated virus (AAV) therapies, marking a significant development in gene therapy manufacturing.
With six FDA-approved AAV therapies already available and more nearing approval, the demand for efficient and cost-effective upstream manufacturing solutions continues to grow. AAV-based therapies have emerged as a cornerstone of gene therapy, but developers face ongoing challenges in scaling production while maintaining quality and controlling costs.
KyFect™ – AAV is designed to address those issues by enhancing plasmid DNA binding and controlled release during the transfection process. According to Kyfora Bio, the reagent is optimized for flexibility and reproducibility across the entire product lifecycle, from early research to full-scale GMP manufacturing. The company emphasized that the technology enables higher viral titers, improved efficiency, and greater consistency in production.
“KyFect™ – AAV was developed with our customers’ entire product lifecycle in mind,” said Leena Mol Thuruthippallil, PhD, Vice President of Commercial Strategy and Development at Kyfora Bio. “From early discovery to GMP manufacturing, our reagents empower gene therapy developers to achieve higher titers with fewer resources, accelerating timelines and reducing costs without compromising quality.”
The launch builds on Kyfora Bio’s heritage under Polysciences, a firm with deep expertise in specialty chemical manufacturing. With gene therapy continuing to expand as a leading area of innovation, KyFect™ – AAV positions the company to play a pivotal role in supporting biopharmaceutical developers seeking scalable, reliable, and cost-efficient solutions.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.